Brugada syndrome drugs to avoid: Difference between revisions
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
The following drugs should be avoided in patients with Brugada syndrome. <ref>www.brugadadrugs.org</ref><ref name="pmid19716089">{{cite journal |author=Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA |title=Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org) |journal=[[Heart Rhythm : the Official Journal of the Heart Rhythm Society]] |volume=6 |issue=9 |pages=1335–41 |year=2009 |month=September |pmid=19716089 |pmc=2779019 |doi=10.1016/j.hrthm.2009.07.002 |url=http://linkinghub.elsevier.com/retrieve/pii/S1547-5271(09)00739-5 |issn= |accessdate=2012-10-13}}</ref> | The following drugs should be avoided in patients with Brugada syndrome. <ref>www.brugadadrugs.org</ref><ref name="pmid19716089">{{cite journal |author=Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA |title=Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org) |journal=[[Heart Rhythm : the Official Journal of the Heart Rhythm Society]] |volume=6 |issue=9 |pages=1335–41 |year=2009 |month=September |pmid=19716089 |pmc=2779019 |doi=10.1016/j.hrthm.2009.07.002 |url=http://linkinghub.elsevier.com/retrieve/pii/S1547-5271(09)00739-5 |issn= |accessdate=2012-10-13}}</ref> | ||
<font size="- | <font size="-1"> | ||
{| cellspacing="2" cellpadding="3" border="0" | {| cellspacing="2" cellpadding="3" border="0" | ||
|- | |- | ||
Revision as of 22:58, 13 October 2012
|
Brugada syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Brugada syndrome drugs to avoid On the Web |
|
American Roentgen Ray Society Images of Brugada syndrome drugs to avoid |
|
Risk calculators and risk factors for Brugada syndrome drugs to avoid |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The following drugs should be avoided in patients with Brugada syndrome. [1][2]
| Generic name | Brand name® | Class / Clinical use | References | Recommendation |
| Ajmaline | e.g. Gilurytmal® - more brand names here - |
Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias | Brugada 1997 Rolf 2003 Wolpert 2005 Bébarová 2005 |
Class I |
| Flecainide | e.g. Tambocor® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Krishnan 1998 Brugada 2000 Gasparini 2003 Meregalli 2006 Stokoe 2007 |
Class I |
| Pilsicainide | e.g. Sunrhythm® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Takenaka 1999 Fujiki 1999 Takagi 2002 Kimura 2004 |
Class I |
| Procainamide | e.g. Procan® Pronestyl® - more brand names here - |
Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias | Miyazaki 1996 Brugada 1997 Joshi 2007 Villemaire 1992 |
Class I |
| Propafenone | e.g. Rythmol® - more brand names here - |
Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias | Matana 2000 Akdemir 2002 Hasdemir 2006 Shan 2008 Stark 1996 |
Class IIa |
Recommendation: Class I: convincing evidence/opinion; Class IIa: evidence/opinion less clear; Class IIb: conflicting evidence/opinion; Class III: very little evidence.
References
- ↑ www.brugadadrugs.org
- ↑ Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA (2009). "Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org)". Heart Rhythm : the Official Journal of the Heart Rhythm Society. 6 (9): 1335–41. doi:10.1016/j.hrthm.2009.07.002. PMC 2779019. PMID 19716089. Retrieved 2012-10-13. Unknown parameter
|month=ignored (help)